IL1B and breast carcinoma: Together, these findings provide compelling evidence of a role for IL-1β in tumorigenesis, and highlight the ongoing work needed to identify valid biomarkers in this patient population in order harness the therapeutic potential of IL-1β blockade for patients with breast cancer and other solid tumor malignancies.